边峰博士是百时美施贵宝全球药物研发中国综合科学团队执行总监, 常驻上海。她负责中国针对早期研发的外部合作，主要关注中国以及周边亚洲地区的创新性科学进展包括新靶点，突破性技术，新型有效或高度差异化的临床前分子和疗法，转化医学，并负责与生命科学领域建立密切的合作关系。之前她是辉瑞Emerging Science & Innovation (ES&I)高级总监/中国新兴科学与创新合作负责人。在加入辉瑞之前，边峰博士自2014年起在中国诺华生物医学研究中心担任高级研究员和肝脏疾病临床前药理学平台负责人。在诺华公司，她是项目负责人并管理肝病药理学平台，为中国和全球药物研发项目提供临床前药理数据。在诺华之前，她于2012年加入强生公司，是在上海参与建立生物研究实验室的关键科学家。在强生公司，她担任生物学副总监，参与管理CRO，学术研究合作以及内部研发项目。 边博士的研发生涯起始于美国Parke-Davis / Warner-Lambert公司，担任神经科学部门的临床前体内药理学家，后来成为辉瑞公司在美国的全球研发总部神经科学部门的首席科学家，为Lyrica®等项目做出贡献。她还参与阿尔茨海默病，抑郁症和皮肤纤维化等疾病的创新药物研究。边博士在小分子和生物药物研究方面拥有20多年的专业知识，她的工作支持多个创新药物项目进入人体实验阶段。边博士在俄亥俄州立大学获得生物化学博士学位，并在天津南开大学获得理学学士学位。

Dr. Feng Bian is an Executive Director of Integrative Sciences/China R&D at Bristol Myers Squibb based in Shanghai. She is responsible for scouting and partnering in early R&D space to cultivate strong and in-depth scientific relationships with academic and life science communities with a primary focus on China and nearby regions to access emerging sciences including novel targets, breakthrough technologies, new or highly differentiated preclinical assets, and translation research.

Before this, Dr. Bian was a Senior Director and China Emerging Science Lead in Pfizer Emerging Science & Innovation (ES&I) of Pfizer Worldwide Research, Development & Medical focusing on China and nearby Asia regions. Prior to Pfizer ES&I, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for worldwide drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principal scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has more than 20 years of expertise in small molecule and biologics drug discovery and her work has enabled several NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.